Macular Degeneration

Health written question – answered on 24th January 2008.

Alert me about debates like this

Photo of Andrew Dismore Andrew Dismore Labour, Hendon

To ask the Secretary of State for Health what progress has been made by the National Institute for Health and Clinical Excellence on decisions relating to treatment for macular degeneration.

Photo of Ann Keen Ann Keen Parliamentary Under-Secretary (Health Services), Department of Health

The National Institute for Health and Clinical Excellence (NICE) has published a second Appraisal Consultation Document (ACD) on Lucentis (ranibizumab) and Macugen (pegaptanib) for the treatment of wet age-related macular degeneration. Stakeholders had until 14 January 2008 to provide comments on the ACD and these comments will be considered by NICE's Appraisal Committee before the guidance is finalised. NICE expects to publish its final guidance later in 2008.

Further detailed information on this appraisal is available on NICE's website at:

http://guidance.nice.org.uk/page.aspx?o=207024

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.